Sentences with phrase «for studying drug»

The simplified platform eliminates the need for pumping and tubing connections and provides a novel, easy - to - use platform for studying drug metabolism, toxicity and interactions between multi-tissue systems, serving as a robust, valuable tool for screening drugs for toxic effects.

The study, reported in today's Science, suggests a new avenue for studying drug addiction.

Not exact matches

A small 2006 study found ginkgo was as effective as the drug donepezil for boosting attention and memory in people with mild to moderate Alzheimer's.

While the new mid-stage study results from DNDi were impressive (they showed cure rates of 96 % to 97 % even for the sickest patients and those with liver scarring), more late - stage trials will be necessary before the drug is available on a large scale in the developing world.

A new study published in the New England Journal of Medicine finds that Valeant Pharmaceuticals» infamous price hikes for a pair of heart drugs called nitroprusside and isoproterenol — whose prices were increased by 310 % and 720 %, respectively — had significant downstream effects on patient care.

The striking example I focused on then was the cancer drug Avastin, developed by Genentech (now Roche)-- which, at the time, had been studied in at least 400 completed human clinical trials for various cancers.

Topics included: early reporting on inaccuracies in the articles of The New York Times's Judith Miller that built support for the invasion of Iraq; the media campaign to destroy UN chief Kofi Annan and undermine confidence in multilateral solutions; revelations by George Bush's biographer that as far back as 1999 then - presidential candidate Bush already spoke of wanting to invade Iraq; the real reason Bush was grounded during his National Guard days — as recounted by the widow of the pilot who replaced him; an article published throughout the world that highlighted the West's lack of resolve to seriously pursue the genocidal fugitive Bosnian Serb leader Radovan Karadzic, responsible for the largest number of European civilian deaths since World War II; several investigations of allegations by former members concerning the practices of Scientology; corruption in the leadership of the nation's largest police union; a well - connected humanitarian relief organization operating as a cover for unauthorized US covert intervention abroad; detailed evidence that a powerful congressional critic of Bill Clinton and Al Gore for financial irregularities and personal improprieties had his own track record of far more serious transgressions; a look at the practices and values of top Democratic operative and the clients they represent when out of power in Washington; the murky international interests that fueled both George W. Bush's and Hillary Clinton's presidential campaigns; the efficacy of various proposed solutions to the failed war on drugs; the poor - quality televised news program for teens (with lots of advertising) that has quietly seeped into many of America's public schools; an early exploration of deceptive practices by the credit card industry; a study of ecosystem destruction in Irian Jaya, one of the world's last substantial rain forests.

Studies commissioned by his group project that over the next decade, PBMs will save employers, consumers, and the government more than $ 2 trillion, and have already helped reduce by a third the projected cost of the Medicare Part D program, a largely privatized drug benefit for seniors.

LAGUNA NIGUEL, Calif. — The cost to develop and gain FDA approval for a new drug today is more than $ 2.5 billion, according to the Tufts Center for the Study of Drug Developmdrug today is more than $ 2.5 billion, according to the Tufts Center for the Study of Drug DevelopmDrug Development.

And Marathon barely did any actual clinical legwork to get the drug cleared for Duchenne — it relied on 1990 - era clinical trial data before tacking on just enough study material to win an approval that doesn't even address the root cause of the disease.

Valeant, however, received an incomplete grade for three follow - up studies required to explore the interaction between the drug and alcohol.

After that, Watson will take assist by providing both physician and patient with a report that includes the most relevant drug trial and academic studies for their specific conditions.

A new government - funded study suggests that addictive opioid painkillers may not be better than other, non-opioid kinds of drugs for treating chronic back pain and arthritis.

But while thousands of clinical trials on immunotherapy drugs, of which many are predicted to fail, are springing up, the depth of information on neoantigen vaccines is much shallower: Just two studies on neoantigen vaccines for melanoma, recently profiled in Nature, were completed last year in Boston and Germany.

«The DEA appears to be dragged into this kicking and screaming,» said Sanho Tree, director of the Drug Policy Project at the Institute for Policy Studies, a progressive think tank focused on social - justice issues.

Phase I funding — which allows up to $ 250,000 for an academic idea, such as decoding the genetic sequence of a protein or studying targeted drug delivery by using magnetic nanoparticles — is available from federal funding and foundations.

The company is chasing an at least $ 80 million IPO to help fund the phase 3 studies that would be necessary for the Food and Drug Administration (FDA) to clear the treatment (the company has made modifications to the experimental, once - a-day pill that fights brain plaque buildup associated with Alzheimer's).

But according to the Government Accountability Office (GAO) which did a study in 2013 on the drug shortage, other reasons include a lack of materials to make the drugs, as well as delays in getting government approval for new and experimental drugs.

For future studies, they suggested, researchers should test the performance of doped chess players given a much longer time limit, so the study could isolate the positive effects of brain drugs.

The Food and Drug Administration (FDA) has given Alnylam Pharmaceuticals the green light to relaunch clinical trials of its treatment for the bleeding disorder hemophilia after pausing the studies after a patient death.

For industries like healthcare, Larsen points out that various studies have found that the most «satisfied» patients are also those who spent the most on prescription drugs and were 12 percent more likely to be admitted to hospitals.

The drug is called Acthar, and for the past year it has been the focus of a study by the Oregon Health and Science University School of Medicine and Oregon State that has been trying to understand why doctors keep prescribing it for ailments it has never been proved to treat effectively.

Agios Pharmaceuticals shares plunged more than 18 percent after the company discontinued development of an experimental drug for rare blood disorder due to side effects seen in a study.

The DEA will now conduct its own eight - factor analysis to study the drug's potential for abuse, the current state of medical and scientific knowledge, the history and pattern of abuse, and other considerations.

These risks and uncertainties include: Gilead's ability to achieve its anticipated full year 2018 financial results; Gilead's ability to sustain growth in revenues for its antiviral and other programs; the risk that private and public payers may be reluctant to provide, or continue to provide, coverage or reimbursement for new products, including Vosevi, Yescarta, Epclusa, Harvoni, Genvoya, Odefsey, Descovy, Biktarvy and Vemlidy ®; austerity measures in European countries that may increase the amount of discount required on Gilead's products; an increase in discounts, chargebacks and rebates due to ongoing contracts and future negotiations with commercial and government payers; a larger than anticipated shift in payer mix to more highly discounted payer segments and geographic regions and decreases in treatment duration; availability of funding for state AIDS Drug Assistance Programs (ADAPs); continued fluctuations in ADAP purchases driven by federal and state grant cycles which may not mirror patient demand and may cause fluctuations in Gilead's earnings; market share and price erosion caused by the introduction of generic versions of Viread and Truvada, an uncertain global macroeconomic environment; and potential amendments to the Affordable Care Act or other government action that could have the effect of lowering prices or reducing the number of insured patients; the possibility of unfavorable results from clinical trials involving investigational compounds; Gilead's ability to initiate clinical trials in its currently anticipated timeframes; the levels of inventory held by wholesalers and retailers which may cause fluctuations in Gilead's earnings; Kite's ability to develop and commercialize cell therapies utilizing the zinc finger nuclease technology platform and realize the benefits of the Sangamo partnership; Gilead's ability to submit new drug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (the SDrug Assistance Programs (ADAPs); continued fluctuations in ADAP purchases driven by federal and state grant cycles which may not mirror patient demand and may cause fluctuations in Gilead's earnings; market share and price erosion caused by the introduction of generic versions of Viread and Truvada, an uncertain global macroeconomic environment; and potential amendments to the Affordable Care Act or other government action that could have the effect of lowering prices or reducing the number of insured patients; the possibility of unfavorable results from clinical trials involving investigational compounds; Gilead's ability to initiate clinical trials in its currently anticipated timeframes; the levels of inventory held by wholesalers and retailers which may cause fluctuations in Gilead's earnings; Kite's ability to develop and commercialize cell therapies utilizing the zinc finger nuclease technology platform and realize the benefits of the Sangamo partnership; Gilead's ability to submit new drug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (the Sdrug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (the SEC).

Gilead's R&D team brought home a clean sweep for its four Phase III studies adding the experimental drug bictegravir to its backbone HIV therapy.

The project is to take place under the auspices of the Center for Supply Chain Studies, with the goal of bringing pharmaceutical firms into compliance with the Drug Supply Chain Security Act, passed in 2013.

The drug known by the street names Ecstasy or Molly could be a promising treatment for post-traumatic stress disorder, according to a new study.

«The intensifying battle for negotiating power and market share will lead companies to do acquisitions across traditional industry boundary lines,» said Erik Gordon, a professor at the Ross School of Business at the University of Michigan who studies the drug industry.

Over the past three decades, the Tufts Center for the Study of Drug Development has estimated both the cost and the years it takes for companies to develop new medicines.

Lilly outlined in July a likely multi-year delay for its experimental rheumatoid arthritis drug baricitinib, after the U.S. Food and Drug Administration declined to approve the drug, calling for an additional clinical stdrug baricitinib, after the U.S. Food and Drug Administration declined to approve the drug, calling for an additional clinical stDrug Administration declined to approve the drug, calling for an additional clinical stdrug, calling for an additional clinical study.

Last year, the FDA issued final guidance on the use of real - world data for the development of devices, and FDA Commissioner Scott Gottlieb has pledged to issue guidance on real - world data for both pre-and post-marketing drug studies.

It also asks for data on studies comparing the proposed drug to the approved brand - name drug, called the «reference drug,» and asks for data from studies conducted on the generic drug.

Directing emergency funds to areas hit by natural disasters had traditionally been quick bipartisan exercises, but that changed after Hurricane Katrina in 2005 — when the Republican Study Committee, a group of House conservatives, pushed spending cuts to compensate for the approximately $ 200 billion expected in Katrina relief — including cutting farm subsidies, Amtrak funding and postponing the Medicare prescription - drug bill Republicans had approved two years earlier.

That may come as a surprise amid hand - wringing about the spiraling cost of health care, but two new studies, one from research company IMS Health and one from pharmacy benefit manager Express Scripts, show that the amount of money Americans spend on prescription drugs went down in 2012 for the first time in decades.

The startup describes itself as a deep data platform for the study of exosomes, which are small lipid vesicles — air - or fluid - filled cavities — that are excreted from cells and which deliver information that Mantra plans to use to come up with new drug therapies.

In early September, Alnylam stopped giving doses of its fitusiran drug for a rare bleeding disorder to patients enrolled in clinical studies after the death of a patient.

(Reuters)- Alnylam Pharmaceuticals Inc's RNAi - based drug that targets a rare genetic disease met the main goal of a key study, in a breakthrough for the new class of medicines that works by blocking disease - causing proteins.

Alkermes is partnering with Biogen on ALKS 8700, a drug for multiple sclerosis that improves on Biogen's $ 4 billion Tecfidera, and a tolerability study should read out in the first half of 2018, with submission to the FDA expected in the the second half.

George Budwell (Trevena): The clinical - stage biotech Trevena is set to release top - line results from two phase 3 studies (APOLLO - 1 and APOLLO - 2) for its lead drug candidate, oliceridine, in the first quarter of 2017.

What: Shares of Alkermes (NASDAQ: ALKS) shed up to 43 % of their value on extraordinary volume in early morning trading today after the company announced that its orally administered drug ALKS - 5461, indicated for major depressive disorder (MDD), failed to meet its primary endpoints in two late - stage studies.

Augros, a professor of philosophy at the Center for Higher Studies in Thornwood, New York, pointed to scientific studies that suggested the active drug in Plan B — levonorgestrel — could function not only as a contraceptive, but as an abortifStudies in Thornwood, New York, pointed to scientific studies that suggested the active drug in Plan B — levonorgestrel — could function not only as a contraceptive, but as an abortifstudies that suggested the active drug in Plan B — levonorgestrel — could function not only as a contraceptive, but as an abortifacient.

There I learned of 17 Protestant and Roman Catholic clergy whose weekly time for breakfast, prayer and textual study is life - giving for ministries that take on poverty, crime, drugs and AIDS.

For example, black pastors question how the Society for the Study of Black Religion really can understand the religion of blacks when absent from this group are black preachers who minister to those who are unemployed, underemployed, addicted to alcohol and drugs, illiterate and apathetFor example, black pastors question how the Society for the Study of Black Religion really can understand the religion of blacks when absent from this group are black preachers who minister to those who are unemployed, underemployed, addicted to alcohol and drugs, illiterate and apathetfor the Study of Black Religion really can understand the religion of blacks when absent from this group are black preachers who minister to those who are unemployed, underemployed, addicted to alcohol and drugs, illiterate and apathetic.

John Ehrlichman, Nixon's domestic policy adviser, later confessed to Dan Baum, author of another trenchant study of drugs, Smoke and Mirrors (1996), that Nixon's election team was looking for scapegoats.

Trauma is what most don't understand, In fact studies point to «childhood trauma» as responsible for over 80 % of all chaos in society; drug addition, alcoholism, lawlessness...

I have a bachelor degree in social studies and worked for many years with people at group homes in Denmark and experienced everyday how focused the doctors were on trying to cure the patients with drugs.

For example, C.L. Winek conducted a study that was published in Drug and Chemical Toxicology that examined the overdose potential of Tabasco ® Sauce.

(Note that it was equal to the drug, and studied for major depression, which is not what it had been recommended for.)

RBT contracted Medicus Research, the premier contract research organization for the Dietary Supplement, Functional Foods and Botanical Drug industries, to perform a comprehensive analysis of independent studies conducted on behalf of RBT to substantiate numerous important health claims for its proprietary and process patented rice bran derivatives and products.